Chronic gout: epidemiology, disease progression, treatment and disease burden.
about
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaThe emerging role of biotechnological drugs in the treatment of goutWhat Outcomes are Important for Gout Patients? In-Depth Qualitative Research into the Gout Patient Experience to Determine Optimal Endpoints for Evaluating Therapeutic Interventions.Gout, genetics and ABC transporters.A Systematic Review of the Economic and Humanistic Burden of Gout.Characteristics of the first metatarsophalangeal joint in gout and asymptomatic hyperuricaemia: a cross-sectional observational study2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.Long-term safety of pegloticase in chronic gout refractory to conventional treatment.A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout.Pegloticase: a novel agent for treatment-refractory gout.Evaluation and treatment of gout as a chronic disease.Chronic gout in the elderly.Multiarticular chronic tophaceous gout with severe and multiple ulcerations: a case report.Management of gout in the real world: current practice versus guideline recommendations.A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.Longitudinal transition trajectory of gouty arthritis and its comorbidities: a population-based study.A profile of gout patients in Sarawak.Allopurinol use in a New Zealand population: prevalence and adherence.Management of hyperuricemia through dietary polyphenols as a natural medicament: A comprehensive review.Evaluation of healthcare costs and utilization for patients with gout: a population-based matched cohort study.Clinical characteristics of foot ulceration in people with chronic gout.Experiences of gout-related disability from the patients' perspective: a mixed methods study.The effect of gout on health-related quality of life, work productivity, resource use and clinical outcomes among patients with hypertension.Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.Risk factors for ulceration over tophi in patients with gout.Physiology of Hyperuricemia and Urate-Lowering Treatments.Urate–lowering therapy: uricases
P2860
Q24612292-1E510A01-B105-466E-A506-7F8B70B0AA21Q26825459-74472A39-AAB1-4E5E-AC30-A607A4940709Q30835709-99B68B77-3724-45F4-88B9-B4F850F49CE5Q35508210-9236966D-8BFC-4918-A142-7747FB8DD82AQ35629910-19060890-66EF-489B-B0FE-F400245E4232Q35964755-09DEB6B7-4A63-4599-8BB2-8DE36A958171Q36870924-B1D2FE2C-CF2B-4372-859B-1343212D310AQ36903272-833E4B98-83C0-4CDC-B8FB-4E56A92975BDQ36981450-995DC02E-01C0-4D9A-A692-A81995266C53Q37130088-5903162C-4EE6-4A68-AD83-B79DE6E1A16AQ37456247-5DB44C18-E501-4B21-A854-6F4C9C54D5A8Q37991129-3797965D-B13F-4B49-8C9E-8E19486D5B6EQ38056075-DC96DB88-B2AC-46A5-BC06-8559193A2CD9Q38112326-8C439221-246D-498A-B10E-958F38AF9F4BQ38367231-4BE6D7FA-0DB8-42FF-86EF-81A1127522FDQ40291328-C2D4AE0D-23BA-4F41-B836-D1EB98759831Q40311349-36237886-4646-480A-A439-E907F319BA83Q40412689-255D8905-69A6-43E4-AB10-A3435AE528BDQ45926515-C3DF145A-4A74-4799-95ED-5B191DBB08E8Q46181270-75744EFD-FDD2-4815-B030-7727D46EF9BDQ47218264-5929A4A9-78BA-459A-B62A-A6AC5BBD42C3Q47780242-A552CC33-1D53-4214-A4AA-CAE3DAA0294FQ48081840-EE8A6D2A-9716-4C7C-956F-5C4A99AF7352Q48160536-5A3CE795-04E0-4DAC-9918-AC069DC7C268Q48333943-3501585F-322E-4EA6-84A3-DBE4307A0ACDQ53583024-2B9D2DB0-4C8E-49D4-B9EC-9A959DF1FD16Q54339363-9F6821CE-2EED-451F-BBB5-DF10ECFF9D93Q55163806-1FF098FF-2167-45ED-9004-47DBAF569343Q57076772-45579D04-CE83-4DAE-A571-9999A28FB287
P2860
Chronic gout: epidemiology, disease progression, treatment and disease burden.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Chronic gout: epidemiology, disease progression, treatment and disease burden.
@en
Chronic gout: epidemiology, disease progression, treatment and disease burden.
@nl
type
label
Chronic gout: epidemiology, disease progression, treatment and disease burden.
@en
Chronic gout: epidemiology, disease progression, treatment and disease burden.
@nl
prefLabel
Chronic gout: epidemiology, disease progression, treatment and disease burden.
@en
Chronic gout: epidemiology, disease progression, treatment and disease burden.
@nl
P2093
P1476
Chronic gout: epidemiology, disease progression, treatment and disease burden.
@en
P2093
Anna Forsythe
James E Smeeding
N Lawrence Edwards
Richard A Brook
P304
P356
10.1185/03007995.2010.533647
P407
P577
2010-11-04T00:00:00Z